Therapeutic composition and method of therapeutically treating warm blooded animals therewith

Abstract

The invention provides a novel therapeutic composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of an ethereally monosubstituted monosaccharide having the general formula S--O--Y, wherein S is the residue of a monosaccharide selected from the group consisting of pentoses, hexoses and heptoses and Y is selected from the group consisting of cyclic monovalent nitrogen containing organic radicals and residua and monovalent organic radicals and residua having the general formula ##STR1## wherein R 1 is a divalent organic radical having a linear carbon chain length of about 1-7 carbon atoms and R 2 and R 3 are selected from the group consisting of --H, --OH, --SH, halogen and monovalent organic radicals and residua having a linear carbon chain length of about 1-7 carbon atoms. The invention also provides certain novel ethereally monosubstituted monosaccharides, of which 3--O--3'-(N',N'-dimethylamino-n-propyl)-D-glucose is an example. The novel monosaccharides show striking antiviral activity or other therapeutically valuable properties and are useful as an active ingredient in the above therapeutic composition. The invention further provides a method of therapeutically treating warm blooded animals with the aforementioned therapeutic composition and novel monosubstituted monosaccharides.

I claim: 
     
       1. A .[.novel.]. therapeutic composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount .Iadd.for treating a warm blooded animal .Iaddend.of at least one .[.substance.]. .Iadd.compound .Iaddend.selected from the group consisting of ethereally monosubstituted monosaccharides having the formula S-O-Y, and therapeutically effective and pharmaceutically acceptable organic acid and .[.inoragnic.]. .Iadd.inorganic .Iaddend.acid salts thereof, wherein S is the residue of a .[.monosaccharide selected from the group consisting of pentoses, hexoses and heptoses.]. .Iadd.hexose .Iaddend.and Y is selected from the group consisting of .[.cyclic monovalent nitrogen containing organic radicals.]. .Iadd.piperidyl and pyrrolidyl radicals .Iaddend.and monovalent organic radicals having the general formula ##STR6## wherein R 1  is a divalent organic radical having a .[.linear.]. carbon chain length of about .[.1-7.]. .Iadd.1-4 .Iaddend.carbon atoms and R 2  and R 3  are selected from the group consisting of .[.--H, --OH, --SH, halogen.]. .Iadd.hydrogen .Iaddend.and monovalent organic radicals having a .[.linear.]. carbon chain length of about .[.1-7.]. .Iadd.1-4 .Iaddend.carbon atoms. 
     
     
       2. A .[.novel.]. therapeutic composition in accordance with claim 1 wherein Y is ##STR7## R 1  is a hydrocarbon radical having a .[.linear.]. carbon chain length of 1-3 carbon atoms, and R 2  and R 3  are selected from the group consisting of hydrogen and hydrocarbon radicals having a .[.linear.]. carbon chain length of 1-3 carbon atoms. 
     
     
       3. A .[.novel.]. therapeutic composition in accordance with claim 1 wherein Y is selected from the group consisting of (n-propylamino),   (N',N'-dimethylamino-n-propyl),   (N',N'-dimethylaminoisopropyl),   (N-methyl piperidyl),   (N',N'-dimethylaminoethyl),   (N',N'-diethylaminoethyl), and   (2',N',N'-trimethylamino-n-propyl).   
     
     
       4. A .[.novel.]. therapeutic composition in accordance with claim 1 wherein Y is -(N',N'-dimethylamino-n-propyl). 
     
     
       5. A .[.novel.]. therapeutic composition in accordance with claim 1 wherein the monosubstituted monosaccharide has the formula ##STR8## wherein X and Z are selected from the group consisting of H, OH and hydroxyalkyl groups containing .[.up to 2.]. .Iadd.1 .Iaddend.carbon .[.atoms.]. .Iadd.atom.Iaddend., Y represents the same organic radicals and residua as set out in claim .[.2.]. 1, and one of the OH groups, X or Z in said formula is replaced by .[.-o-Y..]. -.Iadd.O-Y..Iaddend. 
     
     
       6. A .[.novel.]. therapeutic composition in accordance with claim 5 wherein Y is ##STR9## R 1  is a hydrocarbon radical having a .[.linear.]. carbon chain length of 1-3 carbon atoms, and R 2  and R 3  ae selected from the group consisting of hydrogen and hydrocarbon radicals having a .[.linear.]. carbon chain length of 1-3 carbon atoms. 
     
     
       7. A .[.novel.]. therapeutic composition in accordance with claim 5 wherein Y is selected from the group consisting of (n-propylamino),   (N',N'-dimethylamino-n-propyl),   .[.(N',N'-dimethylaminolso-propyl),.]. (.Iadd.N',N'-dimethylaminopropyl).Iaddend.   (N-methyl piperidyl),   (N',N'-dimethylaminoethyl),   (N',N'-diethylaminoethyl), and   (2',N',N'-trimethylamino-n-propyl).   
     
     
       8. A .[.novel.]. therapeutic composition in accordance with claim 5 wherein Y is -(N',N'-dimethylamino-n-propyl). .[.9. A novel therapeutic composition in accordance with claim 5 wherein the monosaccharide in a hexose..]. .[.10. A novel therapeutic composition in accordance with claim 9 wherein Y is ##STR10## R 1  is a hydrocarbon radical having a linear carbon chain length of 1-3 carbon atoms, and R 2  and R 3  are selected from the group consisting of hydrogen and hydrocarbon radicals having a linear carbon 
     
     
        chain length of 1-3 carbon atoms..]. .[.11.  A novel therapeutic composition in accordance with claim 9 wherein Y is selected from the group consisting of (n-propylamino).   (N',N'-dimethylamino-n-propyl),   (N',N'-dimethylaminoisopropyl,   (N-methyl piperidyl),   (N',N'-dimethylaminoethyl),   (N',N'-diethylaminoethyl), and   (2',N',N'-trimethylamino-n-propyl)..]. .[.12. A novel therapeutic composition in accordance with claim 9 wherein Y is   
     
     
        -(N',N'-dimethylamino-n-propyl)..]. 13. A .[.novel.]. therapeutic composition in accordance with claim 5 wherein the monosaccharide is 
     
     
        selected from the group consisting of glucose and galactose. 14. A .[.novel.]. therapeutic composition in accordance with claim 13 wherein the glucose is monosubstituted in the 1-O- or 3-O- position and the 
     
     
        galactose is monosubstituted in the 6-O- position. 15. A .[.novel.]. therapeutic composition in accordance with claim 14 wherein Y is ##STR11## R 1  is a hydrocarbon radical having a .[.linear.]. carbon chain length of 1-3 carbon atoms, and R 2  and R 3  are selected from the group consisting of hydrogen and hydrocarbon radicals having a .[.linear.]. 
     
     
        carbon chain length of 1-3 carbon atoms. 16. A .[.novel.]. therapeutic composition in accordance with claim 14 wherein Y is selected from the group consisting of (n-propylamino),   (N',N'-dimethylamino-n-propyl),   (N',N'-dimethylaminoisopropyl),   (N-methyl piperidyl),   (N',N'-dimethylaminoethyl),   (N',N'-diethylaminoethyl), and   
     
     
       (2',N',N'-trimethylamino-n-propyl). 17. A .[.novel.]. therapeutic composition in accordance with claim 14 wherein Y is 
     
     
        -(N',N'-dimethylamino-n-propyl). 18. A .[.novel.]. therapeutic composition in accordance with claim 13 wherein the monosubstituted monosaccharide is selected from the group consisting of 3-O-3'-(n-propylamino)-D-glucose,   3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucose,   3-O-4'-(N-methyl piperidyl)-D-glucose,   3-O-2'-(N',N'-dimethylaminoethyl)-D-glucose,   3-O-2'-(N',N'-diethylaminoethyl)-D-glucose,   3-O-3'-(2',N'-trimethylamino-n-propyl)-D-glucose, ,N'   α-N,N-dimethylaminoisopropyl-D-glucoside,   6-O-3'-N',N'-dimethylamino-n-propyl)=D-galactose,   3-O-2'-(N',N'-dimethylaminopropyl)-D-glucose, and   
     
     
       6-O-2'-(N',N'-dimethylaminopropyl)-D-galactose. 19. A .[.novel.]. therapeutic composition in accordance with claim 13 wherein the monosubstituted monosaccharide is 
     
     
        3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucose. 20. A method of therapeutically treating .Iadd.a viral infection in .Iaddend.a warm blooded animal comprising therapeutically administering thereto .[.a therapeutically effective amount of.]. at least one .[.substance.]. .Iadd.compound .Iaddend.selected from the group consisting of ethereally monosubstituted monosaccharides having the formula S-O-Y and therapeutically effective and pharmaceutically acceptable organic acid and inorganic acid salts thereof, wherein S is the residue of a .[.monosaccharide selected from the group consisting of pentoses, hexoses and heptoses.]. .Iadd.hexose .Iaddend.and Y is selected from the group consisting of .[.cyclic monovalent nitrogen containing organic.]. .Iadd.piperidyl and pyrrolidyl .Iaddend.radicals and monovalent organic radicals having the formula ##STR12## wherein R 1  is a divalent organic radical having a .[.linear.]. carbon chain length of about .[.1-7.]. .Iadd.1-4 .Iaddend.carbon atoms and R 2  and R 3  are selected from the group consisting of .[.--H, --OH, --SH, halogen.]..Iadd., hydrogen .Iaddend.and monovalent organic radicals having a .[.linear.]. carbon chain length of about .[.1-7.]. .Iadd.1-4 .Iaddend.carbon atoms, said .[.substance.]. .Iadd.compound being administered in an amount which is therapeutically effective to treat such 
     
     
        viral infection. .Iaddend. 21. The method of claim 20 wherein Y is ##STR13## R 1  is a hydrocarbon radical having a .[.linear.]. carbon chain length of 1-3 carbon atoms, and R 2  and R 3  are selected from the group consisting of hydrogen and hydrocarbon having a .[.linear.]. carbon chain 
     
     
        length of 1-3 carbon atoms. 22. The method of claim 20 wherein Y is selected from the group consisting of (n-propylamino),   (N',N'-dimethylamino-n-propyl),   (N',N'-dimethylaminoisopropyl),   (N-methyl piperidyl),   (N',N'-dimethylaminoethyl),   (N',N'-diethylaminoethyl), and   
     
     
       (2',N',N'-trimethylamino-n-propyl). 23. The method of claim 20 wherein Y is 
     
     
        -(N',N'-dimethylamino-n-propyl). 24. The method of claim 20 wherein the monosubstituted monoaccharide has the formula ##STR14## wherein X and Z are selected from the group consisting of H, OH and hydroxyalkyl groups containing .[.up to 2.]. .Iadd.1 .Iaddend.carbon .[.atoms.]. .Iadd.atom.Iaddend., Y represents the same organic radicals and residua as set out in claim 20, and one of the OH groups, X or Z in 
     
     
        said formula is replaced by --O--Y. 25. The method of claim 24 wherein Y is ##STR15## R 1  is a hydrocarbon radical having a .[.linear.]. carbon chain length of 1-3 carbon atoms, and R 2  and R 3  are selected from the group consisting of hydrogen and hydrocarbon radicals having a .[.linear.]. 
     
     
        carbon chain length of 1-3 carbon atoms. 26. The method of claim 24 wherein Y is selected from the group consisting of (n-propylamino),   (N',N'-dimethylamino-n-propyl),   N',N'-dimethylaminoisopropyl),   (N-methyl piperidyl),   (N',N'-dimethylaminoethyl),   N',N'-diethylaminoethyl), and   
     
     
       (2', N',N'-trimethylamino-n-propyl). 27. The method of claim 24 wherein Y is -(N',N'-dimethylamino-n-propyl). .[.28. The method of claim 24 wherein 
     
     
        the monosaccharide is hexose..]. .[.29.  The method of claim 28 wherein Y is ##STR16## R 1  is a hydrocarbon radical having a linear carbon chain length of 1-3 carbon atoms, and R 2  and R 3  are selected from the group consisting of hydrogen and hydrocarbon radicals having a linear carbon 
     
     
        chain length of 1-3 carbon atoms..]. .[.30.  The method of claim 28 wherein Y is selected from the group consisting of (n-propylamino),   (N',N'-dimethylamino-n-propyl),   (N',N'-dimethylaminoisopropyl),   (N-methyl piperidyl),   (N',N'-dimethylaminoethyl),   (N',N'-diethylaminoethyl), and   (2',N',N'-trimethylamino-n-propyl)..]. .[.31. The method of claim 28   
     
     
        wherein Y is -(N',N'-dimethylamino-n-propyl)..]. 32. The method of claim 24 wherein the monosaccharide is selected from the group consisting of 
     
     
        glucose and galactose. 33. The method of claim 32 wherein the glucose is monosubstituted in the 1-O- or 3-O- position and the galactose is 
     
     
        monosubstituted in the 6-O- position. 34. The method of claim 33 wherein Y is ##STR17## R 1  is a hydrocarbon radical having a .[.linear.]. carbon chain length of 1-3 carbon atoms and R 2  and R 3  are selected from the group consisting of hydrogen and hydrocarbon radicals having a .[.linear.]. 
     
     
        carbon chain length of 1-3 carbon atoms. 35. The method of claim 33 wherein Y is selected from the group consisting of (n-propylamino),   (N',N'-dimethylamino-n-propyl),   (N',N'-dimethylamino-isopropyl),   (N-methyl piperidyl),   (N',N'-dimethylaminoethyl),   (N',N'-diethylaminoethyl), and   
     
     
       (2°,N',N'-trimethylamino-n-propyl). 36. The method of claim 33 
     
     
        wherein Y is -(N',N'-dimethylamino-n-propyl). 37. The method of claim 32 wherein the monosubstituted monosaccharide is selected from the group consisting of 3-O-3'-(n-propylamino)-D-glucose,   3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucose,   3-O-4'-(N-methyl piperidyl)-D-glucose,   3-O-2'-(N',N'-dimethylaminoethyl)-D-glucose,   3-O-2'-N',N'-diethylaminoethyl)-D-glucose,   3-O-3'-(2',N',N'-dimethylamino-n-propyl)-D-glucose   α-N,N-dimethylaminoisopropyl-D-glucoside,   6-O-3'-(N',N'-dimethylamino-n-propyl)-D-galactose,   3-O-2'-(N',N'-dimethylaminopropyl)-D-glucose, and   
     
     
       6-O-2'-(N',N'-dimethylaminopropyl)-D-galactose. 38. The method of claim 32 wherein the monosubstituted monosaccharide is 
     
     
        3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucose. 39. A .[.novel.]. therapeutic composition in accordance with claim 1 wherein the said substance is in the form of a salt of an acid selected from the group consisting of HCl, HBr, H 2  SO 4 , HNO 3 , benzoic acid, p-amino-benzoic acid, p-acetamidobenzoic acid p-hydroxybenzoic acid, alkane sulfonic acids, p-toluene sulfonic acid, lower alkyl monocarboxylic acids, oxalic acid, tartaric acid, lactric acid, pyruvic acid, malic acid, 
     
     
        succinic acid, gluconic acid and glucuronic acid. 40. The .[.novel.]. therapeutic composition in accordance with claim 39 wherein the said acid 
     
     
        is HCl. 41. The .[.novel.]. therapeutic composition in accordance with claim 19 wherein the said 3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucose is in the form of a salt of an acid selected from the group consisting of HCl, HBr, H 2  SO 4 , HNO 3 , benzoic acid, p-aminobenzoic acid, p-acetamidobenzoic acid, p-hydroxybenzoic acid, alkane sulfonic acids, p-toluene sulfonic acid, lower alkyl monocarboxylic acids, oxalic acid, tartaric acid, lactic acid, pyruvic acid, malic acid, succine acid, 
     
     
        gluconic acid and glucuronic acid. 42. The .[.novel.]. therapeutic 
     
     
        composition in accordance with claim 41 wherein the said acid is HCl. 43. The method of claim 20 wherein the said substance is in the form of a salt of an acid selected from the group consisting of HCl, HBr, H 2  SO 4 , HNO 3 , benzoic acid, p-aminobenzoic acid, p-acetamidobenzoic acid, p-hydroxybenzoic acid, alkane sulfonic acids, p-toluene sulfonic acid, lower alklyl monocarboxylic acids, oxalic acid, tartaric acid, lactic acid, pyruvic acid, malic acid, succinic acid, gluconic acid and 
     
     
        glucuronic acid. 44. The method of claim 43 wherein the said acid is HCl. 
     
     
         5. The method of claim 38 wherein the said 3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucose is in the form of a salt of an acid selected from the group consisting of HCl, HBr, H 2  SO 4 , HNO 3 , benzoic acid, p-aminobenzoic acid, p-acetamidobenzoic acid, p-hydroxybenzoic acid, alkane sulfonic acids, p-toluene sulfonic acid, lower alkyl monocarboxylic acids, oxalic acid, tartaric acid, lactic acid, pyruvic acid, malic acid, succinic acid, gluconic acid and 
     
     
        glucuronic acid. 46. The method of claim 45 wherein the said acid is HCl. 
     
     
        .Iadd.47.  The method of claim 20 wherein said viral infection is an influenza, a mumps, or a herpes infection and wherein said compound is administered in an amount which is therapeutically effective to treat said influenza, mumps, or herpes infection. .Iaddend. .Iadd.48. The method of claim 21 wherein said viral infection is an influenza, a mumps, or a herpes infection and wherein said compound is administered in an amount which is therapeutically effective to treat said influenza, mumps, or herpes infection. .Iaddend. .Iadd.49. The method of claim 22 wherein said viral infection is an influenza, a mumps, or a herpes infection and wherein said compound is administered in an amount which is therapeutically effective to treat said influenza, mumps, or herpes infection..Iaddend. .Iadd.50. The method of claim 32 wherein said viral infection is an influenza, a mumps, or a herpes infection and wherein said compound is administered in an amount which is therapeutically effective to treat said influenza, mumps, or herpes infection. .Iaddend. .Iadd.51. The method of claim 38 wherein said viral infection is an influenza, a mumps or a herpes infection and wherein said compound is administered in an amount which is therapeutically effective to treat said influenza, mumps, or herpes infection. .Iaddend.